Dr Angela Jennings is a graduate of the University of New South Wales, achieving academic distinction being awarded the University Medal in Medicine. She was the recipient of numerous awards including the Medical Women’s Society of NSW Prize, the Wallace Worth Prize and the Combined Teaching Hospitals Senior Staff Prize. She undertook her Ophthalmology training at Sydney Eye Hospital and Westmead Hospitals from 2001 to 2004, before completing a Medical Retinal Fellowship with Professor Paul Mitchell at Westmead Hospital in Sydney.
Dr Jennings has played a significant role in research, as a treating investigator in the study of new medications that are now widely used to treat conditions such as Age-Related Macular Degeneration. Two of the best-known studies she has been involved in are the Anchor trial and the VIEW-2 study, which were pivotal in introducing Lucentis and Eylea to clinical use.
Dr Jennings has published articles in peer-reviewed scientific publications and has also been a reviewer for the journal Clinical and Experimental Ophthalmology. She is a Visiting Medical Officer at Westmead Hospital and greatly enjoys helping to train a new generation of Ophthalmologists, particularly in mastering the complex skills required for cataract surgery. She has presented at numerous conferences and has a passion for education and teaching. She regularly lectures on Macular Degeneration and other topics to Optometrists, General Practitioners and the general public.
Dr Jennings is an experienced cataract surgeon and is a member of The Australian and New Zealand Society of Retinal Specialists.